[Fundamental and clinical evaluation of imipenem/cilastatin sodium in the perinatal period].
To evaluate the efficacy of imipenem/cilastatin sodium (IPM/CS) in the field of obstetrics and gynecology, fundamental (measurement of IPM/CS concentrations in mothers' milk) and clinical studies were performed. Concentrations of IPM/CS in mothers' milk were measured every 1 hour up to 6 hours after a 30-minute drip infusion of 500 mg/500 mg of IPM/CS. IPM/CS was distributed similarly to other cephalosporins. In the clinical study, a 500 mg/500 mg dose of IPM/CS was administered to 5 patients with puerperal intrauterine infections and to 3 patients with urinary tract infections by a 30-minute drip infusion b.i.d. or t.i.d. Good responses were observed in all 8 patients, though the infections were mild or moderate. From these results, IPM/CS appeared to be a useful drug for the treatment of perinatal infections.
Ito
K
K
Department of Obstetrics and Gynecology, School of Medicine, Gifu University.
Izumi
K
K
Takagi
H
H
Tamaya
T
T
Hayasaki
M
M
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D015377:Cilastatin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007774:Lactation / Q000378:metabolism; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy
D015377:Cilastatin; D015378:Imipenem